Skip to main content
Top
Published in: AIDS and Behavior 2/2021

01-02-2021 | Care | Original Paper

Potential Influences of the COVID-19 Pandemic on Drug Use and HIV Care Among People Living with HIV and Substance Use Disorders: Experience from a Pilot mHealth Intervention

Authors: Karli R. Hochstatter, Wajiha Z. Akhtar, Sarah Dietz, Klaren Pe-Romashko, David H. Gustafson, Dhavan V. Shah, Sarah Krechel, Cameron Liebert, Rebecca Miller, Nabila El-Bassel, Ryan P. Westergaard

Published in: AIDS and Behavior | Issue 2/2021

Login to get access

Abstract

People living with HIV (PLWH) and substance use disorder (SUD) are particularly vulnerable to harmful health consequences of the global COVID-19 pandemic. The health and social consequences of the pandemic may exacerbate substance misuse and poor management of HIV among this population. This study compares substance use and HIV care before and during the pandemic using data collected weekly through an opioid relapse prevention and HIV management mobile-health intervention. We found that during the pandemic, PLWH and SUD have increased illicit substance use and contact with other substance-using individuals and decreased their confidence to stay sober and attend recovery meetings. The proportion of people missing their HIV medications also increased, and confidence to attend HIV follow-up appointments decreased. Optimal support for PLWH and SUD is critical during pandemics like COVID-19, as drug-related and HIV antiretroviral therapy (ART) non-adherence risks such as overdose, unsafe sexual behaviors, and transmission of infectious diseases may unfold.
Literature
1.
go back to reference Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Bio-Medica Atenei Parm. 2020;91(1):157–60. Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Bio-Medica Atenei Parm. 2020;91(1):157–60.
5.
go back to reference Pellowski JA, Kalichman SC, Matthews KA, Adler N. A pandemic of the poor: social disadvantage and the U.S. HIV epidemic. Am Psychol. 2013;68(4):197–209.CrossRef Pellowski JA, Kalichman SC, Matthews KA, Adler N. A pandemic of the poor: social disadvantage and the U.S. HIV epidemic. Am Psychol. 2013;68(4):197–209.CrossRef
10.
go back to reference Hosseinbor M, Yassini Ardekani SM, Bakhshani S, Bakhshani S. Emotional and social loneliness in individuals with and without substance dependence disorder. Int J High Risk Behav Addict. 2014;3(3):e22668.CrossRef Hosseinbor M, Yassini Ardekani SM, Bakhshani S, Bakhshani S. Emotional and social loneliness in individuals with and without substance dependence disorder. Int J High Risk Behav Addict. 2014;3(3):e22668.CrossRef
11.
go back to reference Cohn SE, Jiang H, McCutchan JA, Koletar SL, Murphy RL, Robertson KR, et al. Association of ongoing drug and alcohol use with non-adherence to antiretroviral therapy and higher risk of AIDS and death: results from ACTG 362. AIDS Care. 2011;23(6):775–85.CrossRef Cohn SE, Jiang H, McCutchan JA, Koletar SL, Murphy RL, Robertson KR, et al. Association of ongoing drug and alcohol use with non-adherence to antiretroviral therapy and higher risk of AIDS and death: results from ACTG 362. AIDS Care. 2011;23(6):775–85.CrossRef
12.
go back to reference Leigh BC. Alcohol and unsafe sex: an overview of research and theory. Prog Clin Biol Res. 1990;325:35–46.PubMed Leigh BC. Alcohol and unsafe sex: an overview of research and theory. Prog Clin Biol Res. 1990;325:35–46.PubMed
13.
go back to reference Stall R. The prevention of HIV infection associated with drug and alcohol use during sexual activity. Adv Alcohol Subst Abuse. 1987;7(2):73–88.CrossRef Stall R. The prevention of HIV infection associated with drug and alcohol use during sexual activity. Adv Alcohol Subst Abuse. 1987;7(2):73–88.CrossRef
14.
go back to reference Berg CJ, Michelson SE, Safren SA. Behavioral aspects of HIV care: adherence, depression, substance use, and HIV-transmission behaviors. Infect Dis Clin N Am. 2007;21(1):181–200.CrossRef Berg CJ, Michelson SE, Safren SA. Behavioral aspects of HIV care: adherence, depression, substance use, and HIV-transmission behaviors. Infect Dis Clin N Am. 2007;21(1):181–200.CrossRef
15.
go back to reference Haverkos HW. Infectious diseases and drug abuse. Prevention and treatment in the drug abuse treatment system. J Subst Abuse Treat. 1991;8(4):269–75.CrossRef Haverkos HW. Infectious diseases and drug abuse. Prevention and treatment in the drug abuse treatment system. J Subst Abuse Treat. 1991;8(4):269–75.CrossRef
16.
go back to reference Gustafson D, Landucci G, Mctavish F, Kornfield R, Johnson R, Mares M, et al. The effect of bundling medication-assisted treatment for opioid addiction with mHealth: study protocol for a randomized clinical trial. Trials. 2016;17:592.CrossRef Gustafson D, Landucci G, Mctavish F, Kornfield R, Johnson R, Mares M, et al. The effect of bundling medication-assisted treatment for opioid addiction with mHealth: study protocol for a randomized clinical trial. Trials. 2016;17:592.CrossRef
17.
go back to reference Hochstatter KR, Gustafson DH Sr, Landucci G, et al. A mobile health intervention to improve hepatitis c outcomes among people with opioid use disorder: protocol for a randomized controlled trial. JMIR Res Protoc. 2019;8(8):e12620.CrossRef Hochstatter KR, Gustafson DH Sr, Landucci G, et al. A mobile health intervention to improve hepatitis c outcomes among people with opioid use disorder: protocol for a randomized controlled trial. JMIR Res Protoc. 2019;8(8):e12620.CrossRef
20.
go back to reference Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21–30.CrossRef Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21–30.CrossRef
21.
go back to reference StataCorp. Stata statistical software: release 16. College Station: StataCorp LLC; 2019. StataCorp. Stata statistical software: release 16. College Station: StataCorp LLC; 2019.
22.
go back to reference Parienti J-J, Massari V, Descamps D, Vabret A, Bouvet E, Larouzé B, Verdon R. Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy. Clin Infect Dis. 2004;38(9):1311–6. https://doi.org/10.1086/383572.CrossRefPubMed Parienti J-J, Massari V, Descamps D, Vabret A, Bouvet E, Larouzé B, Verdon R. Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy. Clin Infect Dis. 2004;38(9):1311–6. https://​doi.​org/​10.​1086/​383572.CrossRefPubMed
23.
go back to reference Bangsberg DR, Perry S, Charlebois ED, Clark RA, Roberston M, Zolopa AR, Moss A. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001;15(9):1181–3.CrossRef Bangsberg DR, Perry S, Charlebois ED, Clark RA, Roberston M, Zolopa AR, Moss A. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001;15(9):1181–3.CrossRef
24.
go back to reference Hogg RS, Heath K, Bangsberg D, Yip B, Press N, O'Shaughnessy MV, Montaner JSG. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS. 2002;16(7):1051–8.CrossRef Hogg RS, Heath K, Bangsberg D, Yip B, Press N, O'Shaughnessy MV, Montaner JSG. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS. 2002;16(7):1051–8.CrossRef
25.
go back to reference Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med. 1991;131(2):81–7.CrossRef Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med. 1991;131(2):81–7.CrossRef
Metadata
Title
Potential Influences of the COVID-19 Pandemic on Drug Use and HIV Care Among People Living with HIV and Substance Use Disorders: Experience from a Pilot mHealth Intervention
Authors
Karli R. Hochstatter
Wajiha Z. Akhtar
Sarah Dietz
Klaren Pe-Romashko
David H. Gustafson
Dhavan V. Shah
Sarah Krechel
Cameron Liebert
Rebecca Miller
Nabila El-Bassel
Ryan P. Westergaard
Publication date
01-02-2021
Publisher
Springer US
Published in
AIDS and Behavior / Issue 2/2021
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-020-02976-1

Other articles of this Issue 2/2021

AIDS and Behavior 2/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.